Literature DB >> 11571215

The clinical and laboratory features of chronic sensory ataxic neuropathy with anti-disialosyl IgM antibodies.

H J Willison1, C P O'Leary, J Veitch, L D Blumhardt, M Busby, M Donaghy, P Fuhr, H Ford, A Hahn, S Renaud, H A Katifi, S Ponsford, M Reuber, A Steck, I Sutton, W Schady, P K Thomas, A J Thompson, J M Vallat, J Winer.   

Abstract

The clinical and laboratory phenotype of a paraproteinaemic neuropathy syndrome termed chronic sensory ataxic neuropathy with anti-disialosyl IgM antibodies is described in a series of 18 cases. Previous single case reports have outlined some features of this syndrome. All 18 cases were defined by the presence of serum IgM antibodies which react principally with NeuAc (alpha2-8)NeuAc(alpha2-3)Gal-configured disialosyl epitopes common to many gangliosides including GDlb, GD3, GTlb and GQlb. In 17 out of 18 cases, the serum contained benign IgM paraproteins, and in four of these cases at least two IgM paraproteins were present. The IgM antibodies were also cold agglutinins in 50% of cases. The clinical picture comprised a chronic neuropathy with marked sensory ataxia and areflexia, and with relatively preserved motor function in the limbs. In addition, 16 out of 18 cases had motor weakness affecting oculomotor and bulbar muscles as fixed or as relapsing-remitting features. When present in their entirety, these clinical features have been described previously under the acronym CANOMAD: chronic ataxic neuropathy, ophthalmoplegia, IgM paraprotein, cold agglutinins and disialosyl antibodies. This distribution of clinical features is reminiscent of Miller Fisher syndrome, in which acute-phase anti-disialylated ganglioside IgG antibodies are found. Clinical electrophysiology and nerve biopsy show both demyelinating and axonal features. A partial response to intravenous immunoglobulin and other treatments is reported in some cases.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11571215     DOI: 10.1093/brain/124.10.1968

Source DB:  PubMed          Journal:  Brain        ISSN: 0006-8950            Impact factor:   13.501


  37 in total

Review 1.  Advances in the laboratory evaluation of peripheral neuropathies.

Authors:  Mengjing Chloe Huan; Mark Bromberg
Journal:  Curr Neurol Neurosci Rep       Date:  2012-02       Impact factor: 5.081

2.  Antibodies against disialosyl and terminal NeuNAc(alpha2-3)Gal ganglioside epitopes in acute relapsing sensory ataxic neuropathy.

Authors:  Ricard Rojas-Garcia; Eduard Gallardo; Monica Povedano; Noemi de Luna; Jordi Bruna; Candido Juarez; Jordi Diaz-Manera; Juan Antonio Martinez-Matos; Isabel Illa
Journal:  J Neurol       Date:  2008-03-17       Impact factor: 4.849

3.  SIADH in a patient with sensory ataxic neuropathy with anti-disialosyl antibodies (CANOMAD).

Authors:  Raffaele Iorio; Fioravante Capone; Elisabetta Iannaccone; Hugh John Willison; Anna Modoni; Pietro Attilio Tonali; Gabriella Silvestri
Journal:  J Neurol       Date:  2009-03-01       Impact factor: 4.849

4.  Successful treatment with rituximab of one patient with CANOMAD neuropathy.

Authors:  Emilien Delmont; P Y Jeandel; A M Hubert; L Marcq; J Boucraut; C Desnuelle
Journal:  J Neurol       Date:  2009-12-04       Impact factor: 4.849

Review 5.  Autoantibodies in chronic inflammatory neuropathies: diagnostic and therapeutic implications.

Authors:  Luis Querol; Jérôme Devaux; Ricard Rojas-Garcia; Isabel Illa
Journal:  Nat Rev Neurol       Date:  2017-07-14       Impact factor: 42.937

Review 6.  Diagnosis and treatment of chronic acquired demyelinating polyneuropathies.

Authors:  Norman Latov
Journal:  Nat Rev Neurol       Date:  2014-07-01       Impact factor: 42.937

7.  Successful treatment of CANOMAD with IVIg and rituximab.

Authors:  Wolfgang N Löscher; Alexander Woertz; Monika Wallnöfer; Julia V Wanschitz; Gerhard Luef
Journal:  J Neurol       Date:  2013-02-12       Impact factor: 4.849

Review 8.  Advances in the Treatment of Paraproteinemic Neuropathy.

Authors:  Eduardo Nobile-Orazio; Mariangela Bianco; Andrea Nozza
Journal:  Curr Treat Options Neurol       Date:  2017-10-16       Impact factor: 3.598

Review 9.  How I manage monoclonal gammopathy of undetermined significance.

Authors:  Ronald S Go; S Vincent Rajkumar
Journal:  Blood       Date:  2017-11-28       Impact factor: 22.113

Review 10.  Immune-mediated neuropathies.

Authors:  Bernd C Kieseier; Emily K Mathey; Claudia Sommer; Hans-Peter Hartung
Journal:  Nat Rev Dis Primers       Date:  2018-10-11       Impact factor: 52.329

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.